Hans J. Hammers

Also affiliated with Southwestern Medical Center, The University of Texas Southwestern Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 21 papers. Top paper: “Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial”.

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000891

N/A

5.8DataRank · unranked

225 citations

Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles +24 more

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer(2022)10.1002/cncr.34180

N/A

5.5DataRank · unranked

265 citations

David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer(2020)10.1002/cncr.33033

N/A

0.875DataRank · unranked

340 citations

Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi +26 more

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009495

N/A

0.615DataRank · unranked

19 citations

Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir +13 more

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2283

N/A

0.609DataRank · unranked

57 citations

Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer +16 more

Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa064

N/A

0.557DataRank · unranked

40 citations

Michael B. Atkins, Ziad Bakouny, Maria I. Carlo, Charles G. Drake, Eric Jonasch +15 more

Monovalent and Divalent Designs of Copper Radiotheranostics Targeting Fibroblast Activation Protein in Cancer

Cancers(2024)10.3390/cancers16244180

N/A

0.165DataRank · unranked

2 citations

Sashi Debnath, Anjan Bedi, Madhuri Parashar, Paulina Gonzalez, Joshua B. Reus +3 more

Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma

Journal of Clinical Investigation(2024)10.1172/jci176230

N/A

0DataRank · unranked

31 citations

Pedro C. Barata, Andrew Elliott, Mehmet Asım Bilen, Earle F. Burgess, Toni K. Choueiri +16 more

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008293

N/A

0DataRank · unranked

6 citations

Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein +11 more

Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice

Frontiers in Immunology(2024)10.3389/fimmu.2024.1351739

N/A

0DataRank · unranked

6 citations

Yuqiu Yang, Yiqing Wang, David Hsiehchen, Thomas Sheffield, Farjana Fattah +12 more

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

Cancer Discovery(2025)10.1158/2159-8290.cd-24-0991

N/A

0DataRank · unranked

38 citations

Lena V. Wirth, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in Mice

Cancers(2025)10.3390/cancers17050771

N/A

0DataRank · unranked

4 citations

Regan Schuetze, Yuling Deng, Khagendra B. Hamal, Cyprian I. Pavlich, Pouguiniseli E. Tankoano +11 more

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

The Oncologist(2025)10.1093/oncolo/oyaf138

N/A

0DataRank · unranked

0 citations

Neil J. Shah, Matthew T. Campbell, Naomi B. Haas, Ariel Ann Nelson, Moshe Chaim Ornstein +12 more

Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1362

N/A

0DataRank · unranked

0 citations

Miya B. Hugaboom, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment Nephrectomy

medRxiv(2025)10.1101/2025.11.19.25340277

N/A

0DataRank · unranked

0 citations

Alana Christie, Vipul Jarmale, Farzad Tahmasebi, Bingqing Xie, Jeffrey Miyata +9 more

Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001198

N/A

0DataRank · unranked

31 citations

Roy Elias, Joseph Formella, William Schwartzman, Alana Christie, Qi Cai +9 more

PD39-11 IMPROVED SURVIVAL AFTER CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA IN THE CONTEMPORARY IMMUNOTHERAPY ERA: A NATIONAL POPULATION-BASED ANALYSIS

The Journal of Urology(2020)10.1097/ju.0000000000000918.011

N/A

0DataRank · unranked

0 citations

Ryan Hutchinson, Rashed Ghandour, Yuval Freifeld, Dong Fang, Arthur I. Sagalowsky +6 more

Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002642

N/A

0DataRank · unranked

19 citations

Jiajia Zhang, Boyang Zhang, Genevieve J. Kaunitz, Poromendro Burman, Hok-Yee Chan +8 more

Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment

Cancers(2022)10.3390/cancers14174208

N/A

0DataRank · unranked

8 citations

Regan Schuetze, Jeni Gerberich, Ramona Lopez, Samuel O. Odutola, Rajendra P. Tanpure +9 more

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.604

N/A

0DataRank · unranked

5 citations

Opeyemi A. Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asım Bilen, Mark N. Stein +11 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Annals of Oncology(2024)10.1016/j.annonc.2024.07.727

N/A

0DataRank · unranked

198 citations

Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more